From: Targeting autophagy to overcome drug resistance: further developments
Therapeutic antibodies | Targets | Combination therapy | Indications | References |
---|---|---|---|---|
Rituximab | CD20 | CQ | Non-Hodgkin lymphoma | [151] |
Bevacizumab | VEGF | CQ | HCC | [152] |
Cetuximab | EGFR | CQ | Vulvar squamous carcinoma | [147] |
Overexpressed Bcl-2 | Colorectal adenocarcinoma | |||
siRNA ATG7 | Lung adenocarcinoma | |||
siRNA Beclin1 | ||||
Gemtuzumab ozogamicin | CD33 | PP242 | Acute myeloid leukemia | [153] |
AZD2014 | [154] | |||
DN30 | Met | Baf | Cardiomyoblasts | [155] |
DO24 | ||||
Trastuzumab | HER2 | CQ | Breast cancer | [148] |
Milatuzumab | CD74 | FTY720 | Mantle cell lymphoma | [156] |
Tositumomab | CD20 | Overexpressed Bcl-2 | B cell malignancies | [157] |
siRNA Beclin1 | ||||
siRNA ATG 12 | ||||
CH12 | EGFRvIII | siRNA ATG7 | HCC | [158] |
siRNA Beclin1 | ||||
β2M mAb | β2-microglobulin | Bortezomib | Multiple myeloma | [159] |
PD-1 mAb | PD-1 | Pemetrexed + sildenafil | Non-small cell lung cancer | [160] |
CTLA4 mAb | CTLA4 |